STOCK TITAN

Clover Health Investments (CLOV) Stock Price, News & Analysis

CLOV NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
36 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+16.4% close of May 28, 2026
1-year change
+100.4% closing prices, November 14, 2025 to November 16, 2026
1-month change
+10.5% closing prices, October 16, 2026 to November 16, 2026

Company Description

Clover Health Investments, Corp. (Nasdaq: CLOV) is a physician enablement technology company operating in the Medicare Advantage market. The company focuses on bringing access to great healthcare to people on Medicare, with particular attention to seniors who have historically lacked access to affordable, high-quality care. Clover Health combines a Medicare Advantage insurance business with a proprietary technology platform designed to support clinical decision-making and chronic disease management.

Clover Health operates through an Insurance segment that offers PPO and HMO Medicare Advantage plans in several states. The company places a differentiated emphasis on its wide-network, high-choice PPO plans,> which are positioned to give members broad provider choice. According to company disclosures, Clover’s Medicare Advantage offerings are built around principles of affordability, flexibility, predictability, and value, including access to extra benefits such as fitness, dental, vision, and hearing, and programs like LiveHealthy Rewards and Clover Care Services for members with complex or acute needs.

Technology-Driven Physician Enablement

A central element of Clover Health’s model is its software platform, historically known as Clover Assistant. This platform is designed to aggregate patient data from across the healthcare ecosystem and surface clinically intuitive insights to primary care physicians (PCPs) at the point of care. By supporting early identification and management of chronic diseases, Clover Assistant is intended to improve health outcomes and influence total cost of care for Medicare Advantage members.

Clover Health has expanded this technology beyond its own plans through its subsidiary Counterpart Health, Inc., described as an AI-powered physician enablement platform. Counterpart Health’s flagship software, Counterpart Assistant, is used by third-party clinicians across multiple states. Company communications state that Counterpart Assistant delivers unified data and real-time insights into clinician workflows, supporting proactive, longitudinal care and value-based care models, including in socioeconomically disadvantaged and resource-constrained settings.

Medicare Advantage Focus and Plan Design

Clover Health’s Medicare Advantage plans are structured around four stated principles:

  • Affordability – including $0 to low monthly premium Medicare Advantage Prescription Drug (MAPD) PPO plans and $0 premium MA-only plans with Part B giveback options.
  • Flexibility – open access to a large network of hospitals and providers, with no referrals required to see specialists in its PPO offerings.
  • Predictability – an emphasis on simple copays rather than complex coinsurance structures to help members anticipate healthcare expenses.
  • Value – extra benefits and dedicated care support programs, such as fitness and preventive services, and Clover Care Services, which can include welcome-home visits after acute care, cancer support programs, and hospice and palliative care support for members with serious illness.

The company has communicated that it aims to maintain stable or improved benefits for its members over time, and that its growth strategy is concentrated in core markets where Clover Assistant coverage and its home care capabilities are strong.

Quality Metrics and Clinical Outcomes

Clover Health and Counterpart Health regularly publish data and whitepapers describing the clinical impact of their technology. Company materials report that Clover’s flagship PPO Medicare Advantage plan has achieved top HEDIS clinical quality performance among non-SNP PPO plans above a specified membership threshold, and that the plan has been ranked as a #1 PPO nationally on core HEDIS measures in certain periods. Counterpart Health attributes this performance to an AI-driven "flywheel" that combines CA-powered visits, real-time data ingestion from numerous sources, AI-powered HEDIS abstraction, and documentation gap closure tools that support primary care practices.

Published analyses cited by the company indicate associations between primary care physician use of Clover/Counterpart Assistant and earlier diagnosis and management of chronic conditions such as diabetes, chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. In high Area Deprivation Index neighborhoods, company data show higher diagnosis rates and earlier-stage detection for several chronic diseases, as well as lower hospitalization and readmission rates for certain conditions among members attributed to CA-enabled PCPs. These findings are presented by Clover and Counterpart as evidence of their technology’s role in supporting proactive, guideline-aligned care.

Business Model and Financial Orientation

Clover Health describes itself as a physician enablement technology company with a Medicare Advantage insurance platform. Revenue is generated through its Insurance segment, which encompasses its Medicare Advantage PPO and HMO plans. The company’s communications emphasize a strategy of disciplined, core-market growth, strong returning member retention, and improving cohort economics. Clover highlights the interaction between membership growth, adoption of Clover Assistant by PCPs, and earlier disease management as key drivers of its financial performance.

Company disclosures reference metrics such as Adjusted EBITDA, Adjusted Net income, and Insurance Benefits Expense Ratio (BER) as non-GAAP measures used to evaluate performance. Clover has reported periods of positive Adjusted EBITDA and has communicated expectations around future GAAP Net Income profitability, while also cautioning that such expectations are forward-looking and subject to risks and uncertainties, as detailed in its SEC filings and forward-looking statement disclaimers.

Counterpart Health and Third-Party Expansion

Through Counterpart Health, Clover extends its technology platform beyond its own Medicare Advantage membership to third-party payors and providers. Counterpart positions itself as an AI-powered clinical operating system for value-based care, with capabilities that include integrated ambient scribing, natural language chat over patient histories, proactive visit summaries, and enterprise-level tools for quality operations, population health, and data services.

Company communications indicate that Counterpart Health has seen significant growth in live third-party customer clinicians using Counterpart Assistant across multiple states. Counterpart’s published data and whitepapers emphasize improvements in chronic disease management, reduced acute care utilization, and enhanced clinical quality measures, particularly in underserved and socioeconomically disadvantaged communities.

Corporate Structure and Remote-First Approach

Clover Health Investments, Corp. is incorporated in Delaware and trades on the Nasdaq under the symbol CLOV. According to its SEC filings, the company operates as a remote-first organization and does not maintain a traditional headquarters. For purposes of securities law compliance and stockholder communications, it directs correspondence to specified electronic and agent addresses, as described in its periodic and current reports.

Board and governance disclosures in SEC filings note changes in board composition, such as the departure of long-serving directors, and the company’s stated intention to maintain a strong, diverse, and experienced board to guide its mission and growth.

Regulatory and Reporting Environment

As a publicly traded company in the Medicare Advantage and healthcare technology space, Clover Health is subject to extensive regulation and oversight. Its SEC filings and press releases emphasize that its operations and financial results are influenced by Medicare rules, Centers for Medicare & Medicaid Services (CMS) Star Ratings, rate updates, and policies affecting medical loss ratios and value-based care arrangements. The company regularly issues Form 8-K reports to announce financial results, provide responses to shareholder questions, and disclose material events such as CMS Star Ratings outcomes and board changes.

Stock Performance

$4.95
-0.20%
-0.01
Last updated: November 16, 2026 at 16:00
+100.4%
Performance 1 year

Clover Health Investments (CLOV) closed at $4.95 on November 16, 2026. Over the past 12 months, the price has gained 100.4%.

See what a $1,000 investment in CLOV would be worth today

Average down calculator for CLOV

CLOV Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
817,453
Shares Sold
16
Transactions
Most Recent Transaction
Soares Karen (Chief Legal Officer) sold 19,275 shares @ $4.66 on October 20, 2026

Insider selling at Clover Health Investments over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Clover Health Investments generated $1.9B in revenue in FY2025, operating income reached -$85.5M (-4.4% operating margin), and net income was -$85.5M, reflecting a -4.5% net profit margin. Diluted earnings per share stood at -$0.17. The company generated -$66.9M in operating cash flow. The current ratio was 1.47, measuring current assets divided by current liabilities.

$1.9B
Revenue (FY2025)
-$85.5M
Net Income (FY2025)
-$66.9M
Operating Cash Flow

Upcoming Events

H1
2027
H1 2027 Regulatory

5-Star rating effective

CMS awarded Clover Health a 5‑Star Medicare Advantage PPO rating effective 2027, enabling year‑round enrollment and impacting PY2028 payments.

Clover Health Investments has 1 upcoming scheduled event. The next event, "5-Star rating effective", is expected in H1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the CLOV stock price.

Short Interest History

Last 12 Months

Short interest in Clover Health Investments (CLOV) currently stands at 23.0 million shares, down 11.3% from the previous reporting period, representing 5.5% of the float. Since November 2025, short interest has decreased by 43.6%.

Days to Cover History

Last 12 Months

Days to cover for Clover Health Investments (CLOV) currently stands at 6.7 days, up 26% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 2.5 to 10.1 days.

CLOV Company Profile & Sector Positioning

Clover Health Investments (CLOV) operates in the Healthcare Plans industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing CLOV often look at related companies in the same sector, including Progyny, Inc. (PGNY), Oscar Health, Inc. (OSCR), Alignment Healthcare, Inc. (ALHC), Molina Healthcare, Inc. (MOH), and Centene Corporation (CNC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CLOV's relative position within its industry.

Frequently Asked Questions

The current stock price of Clover Health Investments (CLOV) is $4.95 as of November 16, 2026.

The market cap of Clover Health Investments (CLOV) is approximately $2.7B. Learn more about what market capitalization means .

The FY2025 revenue of Clover Health Investments (CLOV) is $1.9B, from its most recent completed fiscal year.

The FY2025 net income of Clover Health Investments (CLOV) is -$85.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Clover Health Investments (CLOV) is -$0.17 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Clover Health Investments (CLOV) is -$66.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Clover Health Investments (CLOV) is -4.5% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Clover Health Investments (CLOV) is -4.4% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Clover Health Investments (CLOV), current assets divided by current liabilities, was 1.47 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Clover Health Investments (CLOV) is -$85.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

Clover Health Investments, Corp. is a physician enablement technology company focused on people with Medicare. It offers Medicare Advantage PPO and HMO plans in several states and uses its Clover Assistant technology platform to aggregate patient data and support clinical decision-making, with the goal of improving outcomes through early identification and management of chronic disease.

According to company disclosures, Clover Health operates through an Insurance segment that offers PPO and HMO Medicare Advantage plans. Revenue is generated from these Medicare Advantage insurance products, which are supported by the company’s technology-enabled care model.

Clover Assistant is Clover Health’s software platform designed to aggregate patient data from across the healthcare ecosystem and deliver clinically intuitive insights to physicians at the point of care. The company states that it is intended to support early detection and management of chronic diseases and to improve clinical quality and financial performance in its Medicare Advantage population.

Clover Health offers Medicare Advantage PPO and HMO plans in several states. Company materials highlight a differentiated focus on wide-network, high-choice PPO plans, with plan designs that emphasize affordability, flexibility, predictable copays, and additional benefits such as fitness, dental, vision, and hearing coverage, as well as member support programs through Clover Care Services.

Clover Health reports that its Medicare Advantage PPO plan has achieved top HEDIS clinical quality performance among certain PPO plans and that members whose primary care physicians use Clover or Counterpart Assistant show earlier diagnosis and improved management of chronic diseases. The company attributes these outcomes to its AI-enabled technology, real-time data integration, and support for proactive, guideline-aligned care.

Yes. In its SEC filings, Clover Health states that it is a remote-first company and does not maintain a traditional headquarters. For regulatory purposes, it directs stockholder communications to designated electronic and agent addresses, as described in its filings with the Securities and Exchange Commission.

Company whitepapers and press releases from Counterpart Health describe how Counterpart Assistant is used in high Area Deprivation Index neighborhoods and other resource-constrained settings. The data cited by the company show higher diagnosis rates and earlier-stage detection of chronic diseases, as well as lower hospitalization and readmission rates, among patients attributed to primary care physicians using the platform in these communities.

Clover Health’s disclosures indicate that CMS Star Ratings affect payment years for its Medicare Advantage plans and are an important factor in its financial performance. The company has reported specific Star Ratings for its PPO and HMO plans in SEC filings and has highlighted the financial impact of achieving certain Star levels in its guidance and outlook discussions.

Clover Health Investments, Corp. is listed on the Nasdaq stock market under the ticker symbol CLOV. The company files periodic and current reports with the U.S. Securities and Exchange Commission as a publicly traded issuer.